BioLineRx Free Cash Flow Per Share from 2010 to 2024

BLRX Stock  USD 0.30  0.00  0.00%   
BioLineRx Free Cash Flow Per Share yearly trend continues to be fairly stable with very little volatility. Free Cash Flow Per Share will likely drop to -0.03 in 2024. Free Cash Flow Per Share is the amount of cash BioLineRx generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share. View All Fundamentals
 
Free Cash Flow Per Share  
First Reported
2010-12-31
Previous Quarter
(0.02)
Current Value
(0.03)
Quarterly Volatility
0.48734493
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 2.3 M or Selling General Administrative of 17.5 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 8.27. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.
  
Check out the analysis of BioLineRx Correlation against competitors.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Latest BioLineRx's Free Cash Flow Per Share Growth Pattern

Below is the plot of the Free Cash Flow Per Share of BioLineRx over the last few years. It is the amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share. BioLineRx's Free Cash Flow Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow Per Share10 Years Trend
Slightly volatile
   Free Cash Flow Per Share   
       Timeline  

BioLineRx Free Cash Flow Per Share Regression Statistics

Arithmetic Mean(0.28)
Geometric Mean0.20
Coefficient Of Variation(175.84)
Mean Deviation0.33
Median(0.26)
Standard Deviation0.49
Sample Variance0.24
Range2.0723
R-Value0.32
Mean Square Error0.23
R-Squared0.10
Significance0.24
Slope0.04
Total Sum of Squares3.33

BioLineRx Free Cash Flow Per Share History

2024 -0.025
2023 -0.0238
2022 -0.0343
2021 -0.0357
2020 -0.0918
2019 -0.16
2018 -0.32

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's Free Cash Flow Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Free Cash Flow Per Share(0.02)(0.02)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.